

CITATION REPORT

List of articles citing

Functional variants in the gene confer shared effects on risk for Crohnts disease and Parkinsons disease

DOI: 10.1126/scitranslmed.aai7795
Science Translational Medicine, 2018, 10, .

Source: <https://exaly.com/paper-pdf/69221076/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
229	Discovering New Benefits From Old Drugs With Big Data-Promise for Parkinson Disease. 2018 , 75, 917-920		2
228	Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease. 2018 , 75, 939-946		157
227	Crohn's and Parkinson disease: is LRRK2 lurking around the corner?. 2018 , 15, 330-331		8
226	The Microbiome in Neurodegenerative Disease. 2018 , 7, 81-91		5
225	The Nurr1 Ligand, 1,1-bis(3'-Indolyl)-1-(4-Chlorophenyl)Methane, Modulates Glial Reactivity and Is Neuroprotective in MPTP-Induced Parkinsonism. 2018 , 365, 636-651		24
224	Parkinson disease: LRRK2 variants linked to PD and Crohn's disease. 2018 , 14, 126		2
223	Immune system responses in Parkinson's disease: Early and dynamic. 2019 , 49, 364-383		52
222	Physiological and pathological functions of LRRK2: implications from substrate proteins. 2018 , 2, NS20180005	9	
221	Therapies to Slow, Stop, or Reverse Parkinson's Disease. 2018 , 8, S115-S121		14
220	The vermiform appendix impacts the risk of developing Parkinson's disease. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	135
219	New Frontiers in Parkinson's Disease: From Genetics to the Clinic. 2018 , 38, 9375-9382		24
218	The role of neutrophils in the pathogenesis of Crohn's disease. 2018 , 48 Suppl 2, e12983		18
217	Type I Interferons, Autophagy and Host Metabolism in Leprosy. 2018 , 9, 806		18
216	The Enzymatic Core of the Parkinson's Disease-Associated Protein LRRK2 Impairs Mitochondrial Biogenesis in Aging Yeast. 2018 , 11, 205		11
215	Mitochondrial abnormalities in Parkinson's disease and Alzheimer's disease: can mitochondria be targeted therapeutically?. 2018 , 46, 891-909		67
214	Brain and gut: Partners in crime. 2018 , 33, 1098		1
213	An increase in LRRK2 suppresses autophagy and enhances Dectin-1-induced immunity in a mouse model of colitis. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	59

212	Association between inflammatory bowel disease and Parkinson's disease: seek and you shall find?. 2019 , 68, 175-176	12
211	and Parkinson's Disease. 2019 , 10, 758	20
210	The relationship between inflammatory bowel disease and Parkinson's disease: true or fiction?. 2019 , 54, 886-889	0
209	Zebrafish modeling of intestinal injury, bacterial exposures and medications defines epithelial responses relevant to human inflammatory bowel disease. 2019 , 12,	12
208	Comorbidities in inflammatory bowel disease: a call for action. 2019 , 4, 643-654	43
207	Inflammatory Bowel Diseases and Parkinson's Disease. 2019 , 9, S331-S344	40
206	Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease. 2019 , 116, 15616-15624	35
205	The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease. 2019 , 10, 1155	54
204	Innate immune responses to paraquat exposure in a Drosophila model of Parkinson's disease. 2019 , 9, 12714	19
203	Infection triggers symptoms similar to those of Parkinson's disease in mice lacking PINK1 protein. 2019 , 571, 481-482	2
202	Altered Gut Microbiome and Intestinal Pathology in Parkinson's Disease. 2019 , 12, 67-83	36
201	Nonpharmacological Modulation of Chronic Inflammation in Parkinson's Disease: Role of Diet Interventions. 2019 , 2019, 7535472	6
200	alleles modulate inflammation during microbial infection of mice in a sex-dependent manner. <i>Science Translational Medicine</i> , 2019 , 11,	17.5 34
199	Gut Inflammation in Association With Pathogenesis of Parkinson's Disease. 2019 , 12, 218	35
198	Induced pluripotent stem cell-based modeling of mutant LRRK2-associated Parkinson's disease. 2019 , 49, 561-589	13
197	Association of Parkinson's disease and treatment with aminosaliclates in inflammatory bowel disease: a cross-sectional study in a Spain drug dispensation records. 2019 , 9, e025574	8
196	The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration. 2019 , 34, 959-969	37
195	Leucine rich repeat kinase 2: a paradigm for pleiotropy. 2019 , 597, 3511-3521	6

194	Studies on patients establish Crohn's disease as a manifestation of impaired innate immunity. 2019 , 286, 373-388	10
193	Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease. 2019 , 79, 1037-1051	31
192	LRRK2 in Infection: Friend or Foe?. 2019 , 5, 809-815	18
191	Vitamin B modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. 2019 , 29, 313-329	23
190	Pharmacological Autophagy Regulators as Therapeutic Agents for Inflammatory Bowel Diseases. 2019 , 25, 516-537	20
189	Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?. 2019 , 10, 232	30
188	Microbiome changes: an indicator of Parkinson's disease?. 2019 , 8, 38	41
187	LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same. 2019 , 14, 49	55
186	The role of LRRK2 in cell signalling. 2019 , 47, 197-207	23
185	Can the gut be the missing piece in uncovering PD pathogenesis?. 2019 , 59, 26-31	31
184	Biological Functions of Autophagy Genes: A Disease Perspective. 2019 , 176, 11-42	896
183	Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis. 2019 , 42, 4-13	138
182	The risk of Parkinson's disease in inflammatory bowel disease: A systematic review and meta-analysis. 2019 , 51, 38-42	53
181	Emerging views of mitophagy in immunity and autoimmune diseases. 2020 , 16, 3-17	111
180	Is Parkinson's disease a chronic low-grade inflammatory bowel disease?. 2020 , 267, 2207-2213	31
179	The impact of indigenous microbes on Parkinson's disease. 2020 , 135, 104426	17
178	Risk of Parkinson's disease after colectomy: longitudinal follow-up study using a national sample cohort. 2020 , 267, 513-521	3
177	Leucine-rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease. 2020 , 152, 273-283	8

176	Genetics of leprosy: today and beyond. 2020 , 139, 835-846	20
175	LRRK2 and GBA Variants Exert Distinct Influences on Parkinson's Disease-Specific Metabolic Networks. 2020 , 30, 2867-2878	15
174	Innate and adaptive immune responses in Parkinson's disease. 2020 , 252, 169-216	29
173	Inflammatory bowel disease and Parkinson's disease: common pathophysiological links. 2021 , 70, 408-417	24
172	Diet, Microbiota and Brain Health: Unraveling the Network Intersecting Metabolism and Neurodegeneration. 2020 , 21,	16
171	Tau accumulates in Crohn's disease gut. 2020 , 34, 9285-9296	6
170	Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease. 2020 , 21,	39
169	The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases. 2020 , 154, 345-391	10
168	Microglia and astrocyte dysfunction in parkinson's disease. 2020 , 144, 105028	59
167	Comprehensive Genomic Analysis Reveals the Prognostic Role of Copy-Number Variations in Human Malignancies. 2020 , 11,	2
166	The Microbiome as a Modifier of Neurodegenerative Disease Risk. 2020 , 28, 201-222	35
165	The complex pattern of genetic associations of leprosy with HLA class I and class II alleles can be reduced to four amino acid positions. 2020 , 16, e1008818	6
164	Kinase Domain Is a Dynamic Hub for Driving LRRK2 Allosteric. 2020 , 13, 538219	7
163	The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson's Disease. 2020 , 14, 865	12
162	Molecular Footprints of the Immune Assault on Pancreatic Beta Cells in Type 1 Diabetes. 2020 , 11, 568446	5
161	The Michael J. Fox Foundation's Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease. 2020 , 9,	3
160	Structure of LRRK2 in Parkinson's disease and model for microtubule interaction. 2020 , 588, 344-349	60
159	Iroquois Homeobox Protein 2 Identified as a Potential Biomarker for Parkinson's Disease. 2020 , 21,	1

158	Multiple-Hit Hypothesis in Parkinson's Disease: LRRK2 and Inflammation. 2020 , 14, 376	20
157	Evaluation of causality between ADHD and Parkinson's disease: Mendelian randomization study. 2020 , 37, 49-63	3
156	Clostridium difficile infection and risk of Parkinson's disease: a Swedish population-based cohort study. 2020 , 27, 2134-2141	5
155	Leucine Rich Repeat Kinase 2 and Innate Immunity. 2020 , 14, 193	19
154	The gut microbiome in Parkinson's disease: A culprit or a bystander?. 2020 , 252, 357-450	27
153	Distinctive Pathophysiology Underlying Constipation in Parkinson's Disease: Implications for Cognitive Inefficiency. 2020 , 9,	4
152	Pathway paradigms revealed from the genetics of inflammatory bowel disease. 2020 , 578, 527-539	143
151	Inflammatory bowel disease: between genetics and microbiota. 2020 , 47, 3053-3063	24
150	Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease. 2020 , 63, 102-113	40
149	The enteric nervous system: A little brain in the gut 2020 , 26, 31-42	2
148	Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2. 2020 , 28, 406-417.e6	28
147	Parkinson disease and the immune system - associations, mechanisms and therapeutics. 2020 , 16, 303-318	105
146	The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System. 2020 , 14, 227	24
145	Generation of two LRRK2 homozygous knockout human induced pluripotent stem cell lines using CRISPR/Cas9. 2020 , 45, 101804	1
144	Modelling neurodegenerative disease using brain organoids. 2021 , 111, 60-66	11
143	LRRK2 at the pre-synaptic site: A 16-years perspective. 2021 , 157, 297-311	5
142	Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation. 2021 , 36, 25-36	22
141	Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease. 2021 , 36, 449-459	2

140	Leveraging sequence-based faecal microbial community survey data to identify alterations in gut microbiota among patients with Parkinson's disease. 2021 , 53, 687-696	1
139	LRRK2 binds to the Rab32 subfamily in a GTP-dependent manner its armadillo domain. 2021 , 12, 133-146	21
138	The impact of dextran sodium sulphate and probiotic pre-treatment in a murine model of Parkinson's disease. 2021 , 18, 20	9
137	Identification of Targets from LRRK2 Rescue Phenotypes. 2021 , 10,	1
136	Meta-analysis of sample-level dbGaP data reveals novel shared genetic link between body height and Crohn's disease. 2021 , 140, 865-877	1
135	Genetic and Environmental Factors Influence the Pleomorphy of Parkinsonism. 2021 , 22,	8
134	The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance. 2021 , 53, 611-625	7
133	Lower Lymphocyte Count is Associated With Increased Risk of Parkinson's Disease. 2021 , 89, 803-812	10
132	SNPs within microRNA binding sites and the prognosis of breast cancer. 2021 , 13, 7465-7480	0
131	Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort. 2021 , 30, 454-466	4
130	Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pRab10.	
129	The Gut-Brain Axis: Two Ways Signaling in Parkinson's Disease. 2021 , 1	17
128	Early onset leprosy reveals a joint effect of LRRK2 and NOD2 variants.	
127	The role of innate immunity and inflammation in Parkinson's disease. 2021 , 93, e13022	4
126	Is LRRK2 the missing link between inflammatory bowel disease and Parkinson's disease?. 2021 , 7, 26	9
125	Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells. 2021 , 10,	1
124	The Cell Biology of LRRK2 in Parkinson's Disease. 2021 , 41,	6
123	How autophagy controls the intestinal epithelial barrier. 2021 , 1-18	10

122	Common and Rare Variant Prediction and Penetrance of IBD in a Large, Multi-ethnic, Health System-based Biobank Cohort. 2021 , 160, 1546-1557	12
121	Inflamed Ulcerative Colitis Regions Associated With MRGPRX2-Mediated Mast Cell Degranulation and Cell Activation Modules, Defining a New Therapeutic Target. 2021 , 160, 1709-1724	12
120	LRRK2 coding variants and the risk of Parkinson's disease.	
119	Structural analysis of the full-length human LRRK2. 2021 , 184, 3519-3527.e10	26
118	Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10. 2021 , 11, 12900	5
117	The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play. 2021 ,	3
116	LRRK2; a dynamic regulator of cellular trafficking. 2021 , 1761, 147394	0
115	The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α -Synuclein Toxicity in Dopaminergic Neurons In Vivo. 2021 , 22,	6
114	Underwhelming or Misunderstood? Genetic Variability of Pattern Recognition Receptors in Immune Responses and Resistance to. 2021 , 12, 714808	2
113	Impact of the apelin/APJ axis in the pathogenesis of Parkinson's disease with therapeutic potential. 2021 , 99, 2117-2133	5
112	Revisiting the Association Between Inflammatory Bowel Disease and Parkinson's Disease. 2021 ,	2
111	Genetic analysis of four consanguineous multiplex families with inflammatory bowel disease.. 2021 , 9, 521-532	2
110	LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease. 2021 , 11,	6
109	Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology. 2021 , 54, 779-791	2
108	Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology. 2021 , 9, 139	11
107	Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2.	
106	Epigenetic inactivation of the autophagy-lysosomal system in appendix in Parkinson's disease. 2021 , 12, 5134	5
105	Structural Biology of LRRK2 and its Interaction with Microtubules. 2021 , 36, 2494-2504	3

104	Modelling the functional genomics of Parkinson's disease in <i>Caenorhabditis elegans</i> : LRRK2 and beyond. 2021 , 41,	2
103	LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages.	
102	Two helices control the dynamic crosstalk between the catalytic domains of LRRK2.	0
101	Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk. 2021 ,	3
100	The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. 2021 , 172, 105840	17
99	Gut Dysbiosis and Neurological Disorders—An Eclectic Perspective. 2022 , 489-489	
98	Association between inflammatory bowel diseases and Parkinson's disease: systematic review and meta-analysis. 2022 , 17, 344-353	7
97	Altered autophagy on the path to Parkinson's disease. 2022 , 271-286	
96	Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort. 2021 , 15, 634666	0
95	Appendix D—Alpha-synuclein in the gut, Crohn's disease, and the possible protective role of the synucleins in innate immune response. 2021 , 209-226	
94	Parkinson's disease: Genetic-driven therapeutic approaches. 2021 , 135-159	
93	LRRK2 regulation of immune-pathways and inflammatory disease. 2019 , 47, 1581-1595	49
92	Parkinson's Disease-linked LRRK2 structure and model for microtubule interaction.	9
91	Whole-exome analysis in Parkinson's disease reveals a high burden of ultra rare variants in early onset cases.	2
90	Fine-mapping of Parkinson's disease susceptibility loci identifies putative causal variants.	3
89	A powerful method for pleiotropic analysis under composite null hypothesis identifies novel shared loci between Type 2 Diabetes and Prostate Cancer. 2020 , 16, e1009218	12
88	Complex genetic dependencies among growth and neurological phenotypes in healthy children: Towards deciphering developmental mechanisms. 2020 , 15, e0242684	2
87	LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson's. 2020 , 14, 443	21

- 86 A gut bacterial amyloid promotes α -synuclein aggregation and motor impairment in mice. **2020**, 9, 117
- 85 Inflammatory Bowel Disease and Patients With Mental Disorders: What Do We Know?. **2021**, 13, 466-473 1
- 84 Fine-mapping of Parkinson's disease susceptibility loci identifies putative causal variants. **2021**, 4
- 83 Functional screen of Inflammatory bowel disease genes reveals key epithelial functions. 1
- 82 One gene links two different diseases. **2018**, 553, 252-253
- 81 Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease. **2019**,
- 80 Structural basis for Rab8a GTPase recruitment of RILPL2 via LRRK2 phosphorylation of switch 2.
- 79 A genome-wide genetic pleiotropy approach identified shared loci between multiple system atrophy and inflammatory bowel disease.
- 78 Tau accumulates in Crohn's disease gut.
- 77 Identifying novel high-impact rare disease-causing mutations, genes and pathways in exomes of Ashkenazi Jewish inflammatory bowel disease patients.
- 76 LRRK2 to the rescue of damaged endomembranes. **2020**, 39, e106162 0
- 75 Low lymphocyte count is a risk factor for Parkinson's disease.
- 74 Parkinson disease and related disorders. **2020**, 19-30 1
- 73 Mitophagy Balance in Various Cell Subsets in Patients with ANCA-Associated Vasculitis and Correlation with the Presence of Anti-Neutrophil Cytoplasmic Antibodies. **2020**, 31, 366-368
- 72 Interferon- β signaling synergizes with LRRK2 in human neurons and microglia.
- 71 A Powerful Method for Pleiotropic Analysis under Composite Null Hypothesis Identifies Novel Shared Loci Between Type 2 Diabetes and Prostate Cancer. 0
- 70 Gut microbiome dysbiosis is associated with elevated toxic bile acids in Parkinson's disease. 0
- 69 Evaluation of the PREDIGT Score in Discriminating Parkinson Disease from Neurological Health.

68	Mitochondrial dysfunction promotes alternative gasdermin D-mediated inflammatory cell death and susceptibility to infection.	0
67	Neuro-Immunity and Gut Dysbiosis Drive Parkinson's Disease-Induced Pain. 2021 , 12, 759679	0
66	Gastrointestinal mucosal biopsies in Parkinson's disease: beyond alpha-synuclein detection. 2021 , 1	0
65	Functional screen of inflammatory bowel disease genes reveals key epithelial functions. 2021 , 13, 181	2
64	TLR2 and TLR4 in Parkinson's disease pathogenesis: the environment takes a toll on the gut. 2021 , 10, 47	2
63	Intestinal Inflammation and Parkinson's Disease. 2021 , 12, 2052-2068	3
62	High-Throughput Sequencing Haplotype Analysis Indicates in Gene a Potential Risk Factor for Endemic Parkinsonism in Southeastern Moravia, Czech Republic.. 2022 , 12,	
61	INFLAMMATORY BOWEL DISEASE INDUCES α -SYNUCLEIN AGGREGATION IN GUT AND BRAIN.	1
60	Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson's Disease.. 2021 , 10,	3
59	Gut microbiota and inflammation in Parkinson's disease: Pathogenetic and therapeutic insights. 2022 , 20, 1721727X2210837	1
58	LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease.. 2022 , 11, 10	0
57	MEFV and NLRP3 Inflammasome Expression Is Attributed to Immature Macrophages and Correlates with Serum Inflammatory Proteins in Crohn's Disease Patients.. 2022 , 1	1
56	Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2.. 2022 , 119,	2
55	Inflammation and immune dysfunction in Parkinson disease.. 2022 ,	23
54	Immunogenetic Determinants of Parkinson's Disease Etiology.. 2022 ,	
53	Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages.. 2022 , 8, 34	1
52	Convergence of signalling pathways in innate immune responses and genetic form of Parkinson's disease.. 2022 , 105721	0
51	Impact of 98 LRRK2 variants linked to Parkinson's Disease on kinase activity and microtubule binding.	0

50	Extracellular alpha-synuclein: Sensors, receptors, and responses.. 2022 , 168, 105696	1
49	Leucine rich repeat kinase 2 (LRRK2) peptide modulators: Recent advances and future directions. 2022 , 114,	
48	LRRK2 signaling in neurodegeneration: two decades of progress.. 2021 ,	2
47	LRRK2 as a target for modulating immune system responses.. 2022 , 105724	2
46	Data_Sheet_1.PDF. 2020 ,	
45	Data_Sheet_1.pdf. 2018 ,	
44	Table_1.DOCX. 2020 ,	
43	LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domains.. 2022 , 20, e3001427	4
42	Therapeutic potential of leucine-rich repeat kinase 2 inhibitors for Parkinson's disease treatment. 2022 , 623-655	
41	Discovery of 1H-Pyrazole Biaryl Sulfonamides as Novel G2019S-LRRK2 Kinase Inhibitors.	0
40	Neurodegeneration and Neuroinflammation in Parkinson's Disease: a Self-Sustained Loop.	5
39	The microbiome-gut-brain axis in Parkinson disease [from basic research to the clinic.	7
38	The Pathological Mechanism Between the Intestine and Brain in the Early Stage of Parkinson's Disease. 14,	
37	Exploration of the Common Gene Characteristics and Molecular Mechanism of Parkinson's Disease and Crohn's Disease from Transcriptome Data. 2022 , 12, 774	2
36	Neuroprotective approaches to halt Parkinson's disease progression. 2022 , 158, 105380	0
35	Tissue specific LRRK2 interactomes reveal a distinct functional unit within the striatum.	1
34	The LRRK2 signaling network converges on a centriolar phospho-Rab10/RILPL1 complex to cause deficits in centrosome cohesion and cell polarization.	0
33	New Perspectives on Immune Involvement in Parkinson's Disease Pathogenesis. 2022 , 1-7	

32	The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases. 2022 , 172, 105806	0
31	Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson's Disease. 10,	0
30	Molecular mechanisms defining penetrance of LRRK2-associated Parkinson's disease. 2022 , 34, 103-116	
29	Evaluation of the PREDIGT score's performance in identifying newly diagnosed Parkinson's patients without motor examination. 2022 , 8,	
28	Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade. 2022 , 13, 1426	0
27	Mitochondrial ROS promotes susceptibility to infection via gasdermin D-mediated necroptosis. 2022 , 185, 3214-3231.e23	2
26	Discovery of azaspirocyclic 1H-3,4,5-Trisubstituted pyrazoles as novel G2019S-LRRK2 selective kinase inhibitors. 2022 , 114693	0
25	Impact of 100 LRRK2 variants linked to Parkinson's Disease on kinase activity and microtubule binding.	1
24	Genetics and Pathogenesis of Parkinson's Syndrome. 2023 , 18,	1
23	Neuroinflammation and Parkinson's Disease: From Neurodegeneration to Therapeutic Opportunities. 2022 , 11, 2908	5
22	Are neurodegenerative diseases associated with an increased risk of inflammatory bowel disease? A two-sample Mendelian randomization study. 13,	1
21	LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration.	0
20	Comparative and evolutionary analysis of RIP kinases in immune responses. 13,	1
19	LRRK2 expression in normal and pathologic human gut and in rodent enteric neural cell lines.	1
18	The intestinal barrier in disorders of the central nervous system. 2022 ,	3
17	Structure of LRRK1 and mechanisms of autoinhibition and activation.	1
16	LRRK2 Kinase Activity Regulates Parkinson's Disease-Relevant Lipids at the Lysosome.	0
15	LRRK2 Suppresses Lysosome Degradative Activity in Macrophages and Microglia via Transcription Factor E3 Inhibition.	0

- 14 Sex-dependent interactions between prodromal intestinal inflammation and LRRK2 G2019S in mice promote symptoms of Parkinson's disease. ○
- 13 Characterization of Lipopolysaccharide Effects on LRRK2 Signaling in RAW Macrophages. **2023**, 24, 1644 ○
- 12 Is Glial Dysfunction the Key Pathogenesis of LRRK2-Linked Parkinson's Disease?. **2023**, 13, 178 1
- 11 Genetic overlap between Parkinson's disease and inflammatory bowel disease. **2022**, 5, ○
- 10 Towards early detection of neurodegenerative diseases: A gut feeling. 11, ○
- 9 LRRK2: Genetic mechanisms vs genetic subtypes. **2023**, 133-154 ○
- 8 LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease. **2023**, 38, 386-398 1
- 7 Rab12 regulates LRRK2 activity by promoting its localization to lysosomes. ○
- 6 Anti-Inflammatory Effect of Traditional Chinese Medicine on the Concept of Mind-Body Interface. **2023**, 435-458 ○
- 5 LRRK2 Structure-Based Activation Mechanism and Pathogenesis. **2023**, 13, 612 ○
- 4 LRRK2 and Parkinson's disease: from genetics to targeted therapy. ○
- 3 Autoimmunity and Carcinogenesis: Their Relationship under the Umbrella of Autophagy. **2023**, 11, 1130 ○
- 2 Immunological Features of LRRK2 Function and Its Role in the Gut-Brain Axis Governing Parkinson's Disease. **2023**, 1-18 ○
- 1 Identifying high-impact variants and genes in exomes of Ashkenazi Jewish inflammatory bowel disease patients. **2023**, 14, ○